Sort
8,912 grants matching “sars cov 2”
Antiviral Countermeasures Development Center (AC/DC)
$51,914,880George Robert Painter · Emory University · U19 · FY2022 · AI
Integrated Research Facility at Fort Detrick
$50,002,282Sarah Donahue · National Institute Of Allergy And Infectious Diseases · ZIC · FY2025 · AI
Comparative Medicine Infectious Diseases- Bethesda
$49,577,192William Elkins · National Institute Of Allergy And Infectious Diseases · ZIG · FY2025 · AI
IGF::OT::IGF OPERATION OF GOVERNMENT-OWNED CONTRACTOR-OPERATED (GOCO) R&D FACILITIES
$49,100,031John Beigel · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA
Comparative Medicine Infectious Diseases- Bethesda
$46,528,760William Elkins · National Institute Of Allergy And Infectious Diseases · ZIG · FY2024 · AI
Integrated Research Facility at Fort Detrick
$42,480,499Connie Schmaljohn · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI
ACTIV 6
$38,494,599Daniel K Benjamin · Duke University · U24 · FY2021 · TR
Phase 2 COVID-19 Vaccine Variant Clinical Trial
$36,854,858Theresa Engel · Leidos Biomedical Research, Inc. · N01 · FY2022 · AI
RADx-UP CDCC
$36,243,390Michael Cohen-Wolkowiez · Duke University · U24 · FY2021 · MD
Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development
$34,357,967Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR
Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19
$34,000,000Gordon R. Bernard · Vanderbilt University Medical Center · UL1 · FY2020 · TR
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core
$33,203,136Stuart D Katz · New York University School Of Medicine · OT2 · FY2022 · HL
Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A
$32,649,961Andrea Sarah Foulkes · Massachusetts General Hospital · OT2 · FY2024 · HL
Health and Retirement Study: Yrs 35-40
$32,542,439David R. Weir · University Of Michigan At Ann Arbor · U01 · FY2024 · AG
RADx-UP CDCC
$32,364,105Michael Cohen-Wolkowiez · Duke University · U24 · FY2023 · MD
Health and Retirement Study: Yrs 35-40
$31,889,689David R. Weir · University Of Michigan At Ann Arbor · U01 · FY2025 · AG
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
$29,952,323Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
RADX-TECH - LUMINOSTICS, INC. SMARTPHONE-BASED TEST FOR RAPID SARS-COV-2 ANTIGEN DETECTION FROM NASAL SWABS
$28,624,460Bala Raja · Luminostics, Inc. · N02 · FY2021 · HL
Lead optimization
$24,538,508John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2022 · AI
RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)
$24,369,230Stuart Hellyar Hellyar · · N02 · FY2021 · HL
AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION
$24,361,759Hanjoon Ryu · · N02 · FY2021 · HL
RESPIRATORY VIRUSES RESEARCH
$23,310,140John Beigel · Leidos Biomedical Research, Inc. · N01 · FY2017 · CA
Laboratory Support Services
$21,683,567Stephen Migueles · National Institute Of Allergy And Infectious Diseases · ZID · FY2025 · AI
AI-driven Structure-enabled Antiviral Platform (ASAP)
$21,643,949John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2025 · AI
RADX-TECH - ELLUME USA, LLC COVID-19 ANTIGEN TEST FOR THE DIRECT DETECTION OF THE SARS COV-2 VIRUS.
$21,470,000Scott Fry · · N02 · FY2021 · HL